From: Korcuska, Lisa [mailto:Lisa.Korcuska@SanfordHealth.org]
Sent: Tuesday, April 22, 2014 2:51 PM
To: Ivy Baer
Subject: FW: FDA and Part 11 compliance---GOOD NEWS!

From: Toth-Allen, Jean [mailto:Jean.Toth-Allen@fda.hhs.gov]
Sent: Wednesday, May 18, 2011 2:14 PM
To: Korcuska, Lisa
Subject: RE: ACRP

Dear Ms. Korcuska,

FDA does not inspect electronic medical records (EMRs) for Part 11 compliance. The main point about EMRs is that they are developed and maintained by the "institution" for general patient medical records. As such, they are a part of the practice of medicine and FDA does not regulate the practice of medicine. HHS does have an office which is specifically working on a national system for electronic health records - the Office of National Coordinator for Health Information Technology, referred to simply as ONC. (The have a website (http://healthit.hhs.gov/portal/server.pt/community/healthit_hhs_gov/home/1204) if you are interested in them.) Hopefully the system(s) they help develop will have the major elements found in Part 11 that are pertinent to the integrity of data. However, since FDA does not regulate the practice of medicine, we cannot dictate the ground rules for EMRs, even when they hold data relevant to clinical studies. Right now that is mainly information pertinent to inclusion/exclusion criteria and/or in-patient information about a study subject. It is expected that such information will be useable as collected and maintained in the institution's EMRs. We do not expect study sites to provide validation of these systems or any evidence relevant to Part 11. We only ask that FDA investigators be given the ability to review any information in them that is source data for the study in question. As I stated at the forum, we instruct our investigators to have someone at the site bring up the files and allow them to look at them. They may then request for some files or portions of files to be printed out as exhibits for their establishment inspection report (EIR). Using such a process to allow sponsor representatives to review EMRs precludes the temptation to wander around patient files without cause and/or to files of those not involved with study in question.

If you have other questions related to clinical studies, you might find it beneficial to use our official GCP queries box gcp_questions@fda.hhs.gov. It is sorted daily by someone in the office and so if a particular person is on leave you can get an answer without waiting for her return. You may also find it useful to access the set of redacted GCP e-mails found at http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/RepliestoInquiriestoFDAonGoodClinicalPractice/default.htm since we find that many questions and concerns are repeated over time.

Sincerely yours,

Jean Toth-Allen, Ph.D.
Office of Good Clinical Practice
Office of the Commissioner, US FDA

This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.
From: Korcuska, Lisa [mailto:Lisa.Korcuska@SanfordHealth.org]  
Sent: Wednesday, May 18, 2011 1:15 PM  
To: Toth-Allen, Jean  
Subject: ACRP

Dr. Toth-Allen

Last week at the ACRP conference you clarified the FDA stance on EMR’s and Part 11 compliance, could you please clarify for me in an e-mail?

Thank you.

Lisa  
Lisa Korcuska, C.I.P., M.S. | Director of Research Compliance | 605-312-6089

SANFORD HEALTH

Please note that My Email Address Has Changed!  
Please begin using the address in the "From" line above, immediately.  
Soon, email sent to my old address will no longer be delivered to me.

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain privileged and confidential information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.